Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 8/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.38 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | LTK | P29376 | 1/20 | 0.38 |
| ▸ | GRK5 | P34947 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.38 |
| ▸ | NEK4 | P51957 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923616 | 1.00 | MTNR1B (0.49) | MTNR1BMTNR1AEGFRPDPK1PDGFRA | |
| SCHEMBL27947745 | 0.81 | MTNR1B (0.50) | MTNR1BMTNR1APDPK1PDGFRARAB9A | |
| SCHEMBL22766493 | 0.81 | MTNR1B (0.50) | MTNR1BMTNR1AEGFRPDPK1PDGFRA | |
| SCHEMBL3249749 | 0.79 | MTNR1B (0.52) | MTNR1BMTNR1AEGFRPDPK1PDGFRA | |
| SCHEMBL5265681 | 0.79 | MTNR1B (0.51) | MTNR1BMTNR1AMAP4K4NPC1RAB9A | |
| SCHEMBL24916492 | 0.77 | CYP1A1 (0.36) | MTNR1BMTNR1AEGFRPDGFRAMAP4K4 | |
| SCHEMBL29923631 | 0.77 | CYP1A1 (0.36) | MTNR1BMTNR1AEGFRPDGFRAMAP4K4 | |
| SCHEMBL21783691 | 0.77 | MTNR1B (0.51) | MTNR1BMTNR1AEGFRPDGFRADYRK3 | |
| SCHEMBL21783731 | 0.77 | MTNR1B (0.47) | MTNR1BMTNR1AEGFRPDPK1PDGFRA | |
| SCHEMBL14400285 | 0.77 | MTNR1B (0.64) | MTNR1BMTNR1ANPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113651753-A | Synthetic method of 3-methoxyquinoline-5 amine | 上海毕得医药科技股份有限公司 | 2021-11-16 | — | — | CN | claimed |
| US-12577227-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| US-12552786-B2 | Inhibitors of αvβ6 integrin | MORPHIC THERAPEUTIC, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250333371-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-10-30 | — | — | US | disclosed |
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| EP-4532462-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-04-09 | — | — | EP | disclosed |
| CN-119384406-A | Compounds of formula (I) | 赛洛私人有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| EP-4055013-B1 | WDR5 INHIBITORS AND MODULATORS | UNIV VANDERBILT (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2023230649-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-12-07 | — | — | WO | disclosed |
| EP-1799674-A1 | NEW PIPERIDINE ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-27 | — | — | EP | disclosed |
| EP-1799676-A2 | NEW BICYCLIC ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-27 | — | — | EP | disclosed |
| EP-1781650-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006099884-A1 | BETA-AMINOALCOHOL ANTIBIOTICS | ACTELION PERCUREX AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| US-20060205719-A1 | Novel compounds having an antibacterial activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR (DE) | 2006-09-14 | — | — | US | disclosed |
| WO-2006038172-A1 | NEW PIPERIDINE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006032466-A2 | NEW BICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006021448-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2006-03-02 | — | — | WO | disclosed |
| EP-1613624-A2 | NOVEL COMPOUNDS HAVING AN ANTIBACTERIAL ACTIVITY | Morphochem AG Aktiengesellschaft für kombinatorische Chemie (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004089947-A2 | NOVEL COMPOUNDS HAVING AN ANTIBACTERIAL ACTIVITY | MORPHOCHEM AG (DE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205719-A1 | Novel compounds having an antibacterial activity | TOP1, TOP2A, TOP2B | MTNR1B 4307/4885MTNR1A 4496/4885EGFR 4184/4885 |
| US-12552786-B2 | Inhibitors of αvβ6 integrin | ITGB6, ITGB1, ITGA6 | MTNR1B 2059/4885MTNR1A 2840/4885EGFR 668/4885 |
| US-20250333371-A1 | COMPOUNDS | SDHA, PYGB, SLC18A2 | MTNR1B 757/4885MTNR1A 1247/4885EGFR 2773/4885 |
| US-12577227-B2 | WDR5 inhibitors and modulators | WDR1, WDR5, WDR3 | MTNR1B 1342/4885MTNR1A 1165/4885EGFR 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.